



INOVATYON STUDY

Phase III international, randomised study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with relapsed ovarian cancer progressing within 6–12 months of last platinum

Accrual as of 17 October 2016

Trial Update

140 sites opened
410 patients overall



Next steps:

- 100 events recorded for the first interim analysis (futility) – within 2016
- Stop of accrual (about 588 patients) – approx. October 2017

